Wolfgang Hammerschmidt Selected Research

Epstein-Barr Virus Nuclear Antigens

8/2005	Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
9/2004	Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
4/2004	Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
9/2003	The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold.
8/2003	Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Hammerschmidt Research Topics

Disease

17	Infections 11/2022 - 09/2002
14	Neoplasms (Cancer) 09/2020 - 09/2003
9	Epstein-Barr Virus Infections 10/2021 - 04/2004
5	Lymphoma (Lymphomas) 01/2020 - 07/2004
3	Latent Infection 01/2019 - 01/2012
3	Carcinogenesis 03/2014 - 11/2007
2	Inflammation (Inflammations) 09/2020 - 10/2012
2	Hodgkin Disease (Hodgkin's Disease) 12/2005 - 07/2004
2	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2005 - 08/2005
1	Virus Diseases (Viral Diseases) 01/2021
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Leukemia 01/2020
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020
1	Residual Neoplasm 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020
1	Viremia 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2011
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2005
1	Communicable Diseases (Infectious Diseases) 07/2005

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 10/2021 - 09/2003
5	Viral ProteinsIBA 09/2020 - 08/2003
5	Epstein-Barr Virus Nuclear AntigensIBA 08/2005 - 08/2003
4	MicroRNAs (MicroRNA)IBA 01/2021 - 10/2012
4	AntigensIBA 01/2019 - 07/2005
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2002
3	Viral DNAIBA 01/2021 - 01/2010
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 11/2022 - 03/2014
2	Messenger RNA (mRNA)IBA 10/2021 - 05/2012
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 03/2014
2	ChromatinIBA 01/2019 - 01/2015
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2007 - 12/2005
1	A-Form DNA (A-DNA)IBA 11/2022
1	LigandsIBA 10/2021
1	InterferonsIBA 01/2021
1	RibonucleoproteinsIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	CD40 Ligand (CD40L)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Interferon Type IIBA 01/2021
1	pembrolizumabIBA 01/2020
1	Abatacept (Orencia)FDA Link 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	VaccinesIBA 01/2020
1	Death Domain ReceptorsIBA 01/2020
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019
1	Firefly LuciferasesIBA 01/2019
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2014
1	Pharmaceutical PreparationsIBA 05/2014
1	TensinsIBA 05/2014
1	CytokinesIBA 05/2012
1	RNA (Ribonucleic Acid)IBA 05/2012
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2012
1	CytosineIBA 01/2010
1	GuanosineIBA 01/2010
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 12/2005
1	AntibodiesIBA 07/2004
1	ProteomeIBA 04/2004

Therapy/Procedure

2	Immunotherapy 01/2011 - 01/2008
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2020
1	Drug Therapy (Chemotherapy) 01/2020
1	Stem Cell Transplantation 01/2020
1	Transplantation 12/2005